277 related articles for article (PubMed ID: 7555036)
81. Linkage of gut microbiome with cognition in hepatic encephalopathy.
Bajaj JS; Ridlon JM; Hylemon PB; Thacker LR; Heuman DM; Smith S; Sikaroodi M; Gillevet PM
Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(1):G168-75. PubMed ID: 21940902
[TBL] [Abstract][Full Text] [Related]
82. The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study.
De Graeve J; Vanderstraeten E; Delvaeye T; De Lepeleere S; De Somer T; Van Steenkiste C
Acta Gastroenterol Belg; 2022; 85(3):433-437. PubMed ID: 35833904
[TBL] [Abstract][Full Text] [Related]
83. Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study.
Sama C; Morselli-Labate AM; Pianta P; Lambertini L; Berardi S; Martini G
Curr Ther Res Clin Exp; 2004 Sep; 65(5):413-22. PubMed ID: 24672094
[TBL] [Abstract][Full Text] [Related]
84. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
Higuera-de-la-Tijera F; Servín-Caamaño AI; Salas-Gordillo F; Pérez-Hernández JL; Abdo-Francis JM; Camacho-Aguilera J; Alla SN; Jiménez-Ponce F
Can J Gastroenterol Hepatol; 2018; 2018():3015891. PubMed ID: 30079329
[TBL] [Abstract][Full Text] [Related]
85. Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis.
Tatsumi R; Suii H; Yamaguchi M; Arakawa T; Nakajima T; Kuwata Y; Toyota J; Hige S
Intern Med; 2021 May; 60(10):1501-1507. PubMed ID: 33361677
[TBL] [Abstract][Full Text] [Related]
86. Hepatic encephalopathy: pathophysiology and emerging therapies.
Sundaram V; Shaikh OS
Med Clin North Am; 2009 Jul; 93(4):819-36, vii. PubMed ID: 19577116
[TBL] [Abstract][Full Text] [Related]
87. [The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].
Maev IV; V'iuchnova ES; Lebedeva EG; Iakovenko EI; Dicheva DT
Klin Med (Mosk); 2002; 80(5):42-5. PubMed ID: 12087887
[TBL] [Abstract][Full Text] [Related]
88. Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial.
Glal KAM; Abd-Elsalam SM; Mostafa TM
J Hepatobiliary Pancreat Sci; 2021 Oct; 28(10):812-824. PubMed ID: 33768619
[TBL] [Abstract][Full Text] [Related]
89. Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy.
Moon AM; Kim HP; Jiang Y; Lupu G; Bissram JS; Barritt AS; Tapper EB
Am J Gastroenterol; 2023 Feb; 118(2):284-293. PubMed ID: 36730910
[TBL] [Abstract][Full Text] [Related]
90. Persistent portosystemic shunts after liver transplantation causing episodic hepatic encephalopathy.
Barritt AS; Fried MW; Hayashi PH
Dig Dis Sci; 2010 Jun; 55(6):1794-8. PubMed ID: 19655248
[TBL] [Abstract][Full Text] [Related]
91. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
Elfert A; Abo Ali L; Soliman S; Ibrahim S; Abd-Elsalam S
Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1450-1454. PubMed ID: 27512927
[TBL] [Abstract][Full Text] [Related]
92. Editorial: rifaximin and minimal hepatic encephalopathy.
Butterworth RF
Am J Gastroenterol; 2011 Feb; 106(2):317-8. PubMed ID: 21301455
[TBL] [Abstract][Full Text] [Related]
93. ACP Journal Club. Adding rifaximin to lactulose increased reversal and decreased mortality in hepatic encephalopathy.
Kowdley KV; Burman BE
Ann Intern Med; 2013 Oct; 159(8):JC8. PubMed ID: 24126669
[No Abstract] [Full Text] [Related]
94. Rifaximin treatment in hepatic encephalopathy.
Sharma P; Sharma BC
N Engl J Med; 2010 Jun; 362(25):2423-4; author reply 2424-5. PubMed ID: 20578274
[No Abstract] [Full Text] [Related]
95. Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials.
Cai XJ; Wang L; Hu CM
J Cell Biochem; 2018 Nov; 119(10):8336-8345. PubMed ID: 29932239
[TBL] [Abstract][Full Text] [Related]
96. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
Bajaj JS; Sikaroodi M; Shamsaddini A; Henseler Z; Santiago-Rodriguez T; Acharya C; Fagan A; Hylemon PB; Fuchs M; Gavis E; Ward T; Knights D; Gillevet PM
Gut; 2021 Jun; 70(6):1162-1173. PubMed ID: 32998876
[TBL] [Abstract][Full Text] [Related]
97. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
Flamm SL
Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
[TBL] [Abstract][Full Text] [Related]
98. Rifaximin is an efficacious treatment for the Parkinsonian phenotype of hepatic encephalopathy.
Kok B; Foxton MR; Clough C; Shawcross DL
Hepatology; 2013 Oct; 58(4):1516-7. PubMed ID: 23471844
[No Abstract] [Full Text] [Related]
99. Review article: the modern management of hepatic encephalopathy.
Bajaj JS
Aliment Pharmacol Ther; 2010 Mar; 31(5):537-47. PubMed ID: 20002027
[TBL] [Abstract][Full Text] [Related]
100. Lack of Access to Rifaximin Upon Hospital Discharge Is Frequent and Results in Increased Hospitalizations for Hepatic Encephalopathy.
Stoll AM; Guido M; Pence A; Gentene AJ
Ann Pharmacother; 2023 Feb; 57(2):133-140. PubMed ID: 35658580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
